STOCK TITAN

Altimmune - ALT STOCK NEWS

Welcome to our dedicated page for Altimmune news (Ticker: ALT), a resource for investors and traders seeking the latest updates and insights on Altimmune stock.

Altimmune Inc (ALT) is a clinical-stage biopharmaceutical company pioneering peptide-based therapeutics for obesity, metabolic disorders, and liver diseases. This page serves as the definitive source for verified news and press releases directly from the company and trusted financial publications.

Investors and researchers will find timely updates on clinical trial progress, including developments for pemvidutide, the company’s GLP-1/glucagon dual receptor agonist candidate. Track regulatory milestones, partnership announcements, and strategic initiatives that shape Altimmune’s research pipeline.

Our curated news feed includes earnings reports, scientific presentations, and manufacturing updates, providing a holistic view of the company’s trajectory. All content is rigorously vetted to ensure alignment with financial reporting standards and clinical accuracy.

Bookmark this page for efficient access to Altimmune’s latest material events. Check regularly for updates on pivotal studies in metabolic-associated steatohepatitis (MASH) and obesity therapeutics, ensuring you stay informed on developments impacting this innovative biopharma leader.

Rhea-AI Summary

Altimmune presented new data at the EASL International Liver Congress 2024 highlighting the potential of pemvidutide in treating Metabolic Dysfunction-Associated Steatohepatitis (MASH). The data from Phase 1 trials indicate significant improvements in non-invasive tests, suggesting potential histologic benefits by Q1 2025. The trials show that pemvidutide's dual GLP-1/glucagon agonism could outperform GLP-1 alone in resolving MASH and reducing fibrosis. Additionally, lipidomic profiling supports its potential in addressing MASH-related co-morbidities like cardiovascular disease. Pemvidutide is currently being evaluated in a Phase 2b trial.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.08%
Tags
none
-
Rhea-AI Summary

On May 29, 2024, Altimmune (Nasdaq: ALT), a clinical-stage biopharmaceutical company, announced its participation in two upcoming investor conferences. The company management will attend the Jefferies Global Healthcare Conference in New York on June 5, 2024, with a fireside chat at 2:00 p.m. ET. They will also attend the Goldman Sachs Global Healthcare Conference in Miami Beach on June 12, 2024, with a fireside chat at 9:20 a.m. ET. Both sessions will be webcast and accessible via the Events section of Altimmune's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.72%
Tags
conferences
-
Rhea-AI Summary

Altimmune, a clinical-stage biopharmaceutical company, announced new data on pemvidutide, a novel peptide-based GLP-1/glucagon dual receptor agonist, at the EASL International Liver Congress™ 2024 in Milan. Pemvidutide is under development for treating obesity and metabolic dysfunction-associated steatohepatitis (MASH). The data highlights its anti-inflammatory and anti-fibrotic properties in subjects with metabolic dysfunction-associated steatotic liver disease (MASLD). Presentations include:

- Dr. Sarah Browne on metabolic dysfunction-associated steatohepatitis activity and fibrosis.

- Dr. Scot Roberts on plasma lipidomic profiling in subjects with obesity.

- Dr. Shaheen Tomah on noninvasive tests indicating histologic response in MASLD subjects.

These presentations will occur on June 5, 2024, at 8:30 am CEST, with posters displayed throughout the congress.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.72%
Tags
conferences clinical trial
Rhea-AI Summary

Roundhill Investments has launched the Roundhill GLP-1 & Weight Loss ETF (OZEM), now trading on Nasdaq. OZEM targets the growing market of GLP-1 receptor agonists and weight management drugs, which is projected to hit $100 billion by 2030. The ETF offers exposure to companies leading in obesity treatment innovation, including Eli Lilly, Novo Nordisk, and Innovent Biologics. CEO Dave Mazza emphasizes the substantial growth potential due to the rising global obesity rates. Key holdings in the ETF feature major pharmaceutical companies with a focus on weight loss therapeutics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.23%
Tags
none
-
Rhea-AI Summary

Altimmune announced its financial results for the first quarter of 2024, revealing cash, cash equivalents, and short-term investments of $182.1 million as of March 31, 2024. The company highlighted the ongoing IMPACT Phase 2b trial of pemvidutide in MASH, with top-line results expected in Q1 2025. Altimmune also emphasized the upcoming End-of-Phase 2 meeting with the FDA and the positive data from the Phase 2 MOMENTUM trial of pemvidutide in obesity. The company continues to advance enrollment in the IMPACT trial, with topline data anticipated in Q1 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.82%
Tags
-
Rhea-AI Summary

Altimmune, Inc. (Nasdaq: ALT) will participate in two upcoming investor conferences, the JMP Life Sciences Conference in New York on May 14, 2024, and the UBS Obesity Therapeutics Day virtual conference on May 23, 2024. The company's management team will be available for 1x1 meetings and will hold Fireside Chats at specific times. The sessions will be webcast on the Altimmune website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
conferences
Rhea-AI Summary

Altimmune, Inc. (Nasdaq: ALT) will report its first quarter 2024 financial results and provide a business update on May 9, 2024. Altimmune management will host a conference call to discuss the financial results and business update.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.7%
Tags
conferences earnings
-
Rhea-AI Summary

Altimmune, Inc. (Nasdaq: ALT) will be represented by Dr. Scott Harris, Chief Medical Officer, at two upcoming conferences: BTIG Obesity Health Forum and GLP-1-Based Therapeutics Summit. The presentations will focus on emerging therapeutics and the use of GLP-1s in treating MASH & Fatty Liver Disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.94%
Tags
conferences
-
Rhea-AI Summary
Altimmune expresses condolences on the passing of Dr. Stephen Harrison, a key figure in the field of metabolic liver disease. Dr. Harrison's contributions and advocacy for patients will leave a lasting impact on the community.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
none
Rhea-AI Summary
Altimmune, Inc. (ALT) announces positive results from body composition study showing lean mass preservation in obesity trial. Enrollment ongoing in Phase 2b trial for pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis. Preclinical study demonstrates anti-fibrotic effect in liver fibrosis model. Company reports $198.0 million in cash, cash equivalents, and short-term investments. Webcast scheduled for March 27, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.77%
Tags
Altimmune

Nasdaq:ALT

ALT Rankings

ALT Stock Data

350.41M
76.40M
0.84%
53.69%
28.13%
Biotechnology
Pharmaceutical Preparations
Link
United States
GAITHERSBURG